Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat reports.

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

BNP Paribas Exane initiated coverage of Vertex (VERX) with an Outperform rating and $54 price target Stay Ahead of the Market: Discover ...

Zurich-based start-up Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, ...

The deal is a blast from the not-too-distant past, when special purpose acquisition companies were an easy way for companies ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell ...

Citi lowered the firm’s price target on BlackLine to $58 from $70 and keeps a Buy rating on the shares. The firm enters Q1 earnings for the ...

A clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies.

Xlife Sciences says that Veraxa Biotech is to list as a public company on the Nasdaq Global Market through a strategic merger ...

VERAXA's anticipated NASDAQ listing under the ticker "VERX" marks a significant milestone, facilitating access to U.S. capital markets for future growth and expansion. The company has a robust ...

Upon closing of the transaction, VERAXA Biotech AG is expected to list on NASDAQ under the proposed ticker symbol "VERX." VERAXA Overview VERAXA is advancing a premier drug discovery and ...